Aardvark Therapeutics vs Aclaris Therapeutics
Free cash flow was −$54 million at Aardvark Therapeutics and −$47 million at Aclaris Therapeutics.
Side by side
| Aardvark Therapeutics | Aclaris Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $8M |
| Revenue growth | — | −58.2% |
| Revenue growth a year, last 5 years | — | 3.7% |
| Gross margin | — | 73.3% |
| Operating margin | — | −975.9% |
| Net margin | — | −829.6% |
| Free cash flow | −$54M | −$47M |
| Free cash flow margin | — | −603.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 391.1% | 58.6% |
| Last close | $1.00 | $3.50 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $144,630, sold $394,930 | sold $1.4 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aardvark TherapeuticsAclaris Therapeutics
Operating margin
Percent of revenue
Aardvark TherapeuticsAclaris Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aardvark TherapeuticsAclaris Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aardvark Therapeutics and Aclaris Therapeutics pages.